Physician Profile

Saint Luke’s Care Member

Physician Profile

Janakiraman Subramanian, MD

Oncology / Hematology

Education

Medical School
Sri Ramachandra Medical College, Chennal,
Educational Commission for Foreign Medical Graduates
Educational Commission for Foreign Medical Graduates, Philadelphia, PA
Residency
Internal Medicine, St Luke's Hospital Program, Chesterfield, MO
Fellowship
Med/Hematology-Oncol, Washington University/B-JH/SLCH Consortium Program, Saint Louis, MO

Board Certifications

  • American Board of Internal Medicine - Subspecialty in Hematology
  • American Board of Internal Medicine - Subspecialty in Medical Oncology

Clinical Interests

  • lung cancer
  • esophageal cancers
  • head and neck cancer
  • clinical trials
  • outcomes research

Biography

Dr. Janakiraman Subramanian believes in a compassionate approach, coupled with the latest advances in medical science to deliver exceptional care for his patients. In addition to his regular practice, Dr. Subramanian is actively involved in clinical cancer research. He has authored several scientific articles and has been the lead investigator in a number of clinical trials focused on lung cancer.

He specializes in lung, esophageal, head, and neck cancer. 

In addition to his medical degree, Dr. Subramanian has a master’s degree in public health from Wichita State University, in Wichita, Kan. He is board certified by the American Board of Internal Medicine and the American Board of Medical Oncology.

News

MEDIA COVERAGE: Saint Luke's Announces Center for Precision Oncology
Our precision oncology experts treat your tumor’s mutation, not just your cancer’s location. It’s the only program within 450 miles that offers this level of expertise in clinical oncology, tumor genomics, and computational biology.

Accepted Insurances

  • Aetna Choice POS II
  • Aetna Choice POS II Aexcel Local
  • Aetna Choice POS II Local
  • Aetna Elect Choice
  • Aetna Federal Employees Health Benefit Plan
  • Aetna HMO
  • Aetna HMO Local
  • Aetna Mail Handlers Benefit Plan
  • Aetna Managed Choice
  • Aetna MDOT & Missouri State Highway Patrol
  • Aetna Medicare
  • Aetna Missouri Preferred
  • Aetna MU myChoice Health Program
  • Aetna Open Choice PPO
  • Aetna Select
  • Aetna Select Local
  • Aetna Signature Administrators (ASA)
  • Aetna Workers Comp
  • BCBS of Kansas (call provider)
  • BCBS of Kansas City (PPO)
  • BCBS of Kansas City Freedom Network
  • BCBS of Kansas City Freedom Network Select
  • BCBS of Kansas City Preferred Care
  • BCBS of Kansas City Preferred Care Blue
  • BCBS of Kansas City Traditional
  • Beech Street (PPO)
  • Century Health Solutions (PPO)
  • Cigna (HMO)
  • Cigna (Open Access)
  • Cigna (PPO)
  • Cigna HealthSpring (HMO Medicare Advantage)
  • CompResults (WC)
  • Coventry Advantra Freedom (PPO)
  • Coventry Health and Life Insurance Company
  • Coventry Health Care
  • Coventry Medicare Advantra (PPO)
  • Golden Rule
  • Great West HealthCare (POS)
  • Great West HealthCare (PPO)
  • Great West HealthCare One Health Plan
  • Great West HealthCare One Health Plan/Gen AM
  • Health Choice of Northwest Missouri (PPO)
  • Healthcare USA-MC+ (Aetna Better Health)
  • HealthLink (HMO)
  • HealthLink (PPO) through Freedom Network
  • Home State Health Plan (Missouri practices)
  • Humana (PPOx)
  • Humana Choice Care (PPO)
  • Humana Choice PPO (Medicare Advantage PPO)
  • Humana Gold Choice Medicare Advantage PFFS
  • Humana Gold Plus (HMO)
  • Humana Gold Plus HMO SNP
  • Humana SmartExpress PPO
  • Humana SmartNet PPO
  • Humana SmartSuite PPO
  • HumanaOne
  • Integrated Health Plan
  • Kansas Medicaid
  • Medicare
  • Missouri Care (Missouri practices only)
  • Missouri Medicaid
  • MultiPlan/PCHS (PPO)
  • Occupational Health Management (WC)
  • OHARA Managed Care (WC)
  • ProviDRs Care Network (formerly WPPA)
  • Pyramid Life (Medicare Advantage PPO)
  • Railroad Medicare
  • Sunflower State Health Plan (Kansas practices)
  • TRICARE
  • Triwest Veterans Affairs Patient Centered Community Care
  • United Healthcare Choice
  • United Healthcare Choice Plus
  • United Healthcare Community Plan
  • United Healthcare Definity Health Reimbursement Account
  • United Healthcare Definity Health Savings Account
  • United Healthcare Golden Rule HMO
  • United Healthcare Indemnity
  • United Healthcare Managed Indemnity
  • United Healthcare Options PPO
  • United Healthcare Select
  • United Healthcare Select Plus
  • UnitedHealthcare Evercare DH
  • UnitedHealthcare Evercare DH-POS
  • UnitedHealthcare Evercare DP
  • UnitedHealthcare Evercare RDP
  • UnitedHealthcare Medicare Choice
  • UnitedHealthcare Medicare Choice Essential
  • UnitedHealthcare Medicare Complete
  • UnitedHealthcare Medicare Complete Essential
  • UnitedHealthcare Medicare Complete Plus
  • UnitedHealthcare Medicare DH
  • UnitedHealthcare Medicare Plus Essential
  • US Department of Labor

Publications

Selected Publications

Subramanian J, Pillot G, Narra V, Govindan R. Response to bortezomib (Velcade) in a case of advanced bronchiolo-alveolar carcinoma (BAC) A case report. Lung Cancer 2005;51(2):257-259.

Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol 2007;25(5):561-570.

Subramanian J, Velcheti V, Baggstrom MQ, Govindan R. Efficacy of vinorelbine in the second-line setting beyond in non-small cell lung cancer. J Thorac Oncol. 2(4):373; 2007

Subramanian J, Velcheti V, Gao F, Govindan R.  Presentation and stage-specific outcomes of lifelong never-smokers with non-small cell lung cancer (NSCLC): J Thorac Oncol 2007;2(9):827-830.

Subramanian J, Govindan R. Molecular genetics of lung cancer in people who have never smoked. Lancet Oncol. 2008 Jul;9(7):676-82.

Subramanian J, Govindan R. Small cell, big problem! Stem cells, root cause? Clin Lung Cancer. 2008 Sep;9(5):252-3. 

Goodgame B, Viswanathan A, Zoole J, Gao F, Miller R, Subramanian J, Meyers B, Patterson A, Govindan R. Risk of recurrence of resected stage I non-small cell lung cancer in elderly patients as compared to younger patients. Journal of Thoracic Oncology. J Thorac Oncol. 2009 Nov;4(11):1370-4.

Morgensztern D, Waqar S, Subramanian J, Gao F, Govindan R. Improving Survival for stage IV Non-Small Cell Lung cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey From 1990 to 2005. Journal of Thoracic Oncology. J Thorac Oncol. 2009 Dec;4(12):1524-9.

Subramanian J, Morgensztern D, Goodgame B, Baggstrom MQ, Gao F, Piccirillo J, Govindan R. Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: a surveillance, epidemiology, and end results (SEER) analysis. J Thorac Oncol. 2010 Jan;5(1):23-8.

Subramanian J, Govindan R. Chemotherapy: continued lack of progress in SCLC. Nat Rev Clin Oncol. 2010 Feb;7(2):77-8.

Subramanian J, Govindan R. Lung cancer in 'Never-smokers': a unique entity. Oncology (Williston Park). 2010 Jan;24(1):29-35.

Subramanian J, Morgensztern D, Govindan R.  Vascular endothelial growth factor receptor tyrosine      kinase inhibitors in non-small-cell lung cancer.  Clin Lung Cancer 2010 Sep 1; 11(5):311-9.

Subramanian J, Madadi AR, Dandona M, Williams K, Morgensztern D, Govindan R.  Review of ongoing clinical trials in non-small cell lung cancer: a status report for 2009 from the ClinicalTrials.gov website.  J Thorac Oncol 2010 Aug; 5(8):1116-9.  

Subramanian J, Corrales L, Soulieres D, Morgensztern D, Govindan R. Summary of presentations from the 46th annual meeting of the American Society of Clinical Oncology (2010): Focus on tumor biology and biomarkers related to lung cancer.  J Thorac Oncol 2011 Feb; 6(2):399-403.

Cohen EE, Subramanian J et al. Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab and standard chemotherapy for non-small cell lung cancer. A phase II trial. Clin Lung Cancer. 2012 Mar; 13(2): 123-8

Govindan R, Ding L, Griffith M, Subramanian J et al. Genomic landscape of non-small cell lung cancer in smokers and never smokers. Cell. 2012 Sep; 150(6): 1121-34

Ramalingam SS, Owonikoko TK, Behera M, Subramanian J et al. Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer. J Thorac Oncol. 2013 Mar;8(3):369-72.

Subramanian J, Regenbogen T, Nagaraj G, et al. Review of ongoing clinical trials in non-small-cell lung cancer: a status report for 2012 from the ClinicalTrials.gov Web site. J Thorac Oncol. 2013 Jul;8(7):860-5.

Book Chapters

G Pillot, J Subramanian, K Hennefent, and R Govindan. Hematopoietic therapy. In: Govindan R, ed. Cancer: Principles & Practice of Oncology Review. 1st ed. Philadelphia: Lippincott Williams & Wilkins; 2005:467-88.

J Subramanian, R Govindan. Lung Cancer. In: Govindan R, ed. Washington Manual of Oncology. 2nd ed. Philadelphia: Lippincott Williams & Wilkins 2007: 134-148

J Subramanian, V Velcheti. Lung Cancer. In: Wildes T, ed. Subspeciality Manual in Hematology and Oncology. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2008: 204-212

J Subramanian. Neoplasms of the Central Nervous System. Principles & Practice of Oncology Review. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2009: 371-379

J Subramanian. Rehabilitation of the Cancer Patient. Principles & Practice of Oncology Review. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2009: 546-550

J Subramanian, R Govindan. Combination Chemotherapy regimens (Lung Cancer). Pocket Guide to Injectable Chemotherapeutic Agents,  Drug Information and Dosages 5th ed. Midwest Book Publishing; ISBN #:  0-6152310-5-5

J Subramanian, G Linette. Neoplasms of the Central Nervous System. Principles & Practice of Oncology Review. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2012: 383-392

J Subramanian. Rehabilitation of the Cancer Patient. Principles & Practice of Oncology Review. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2012: 573-580

J Subramanian. Systemic Therapy for Salivary Gland Cancer. Salivary Gland Pathology: Diagnosis and Management, Second Edition; Wiley; In Press

Abstracts

Morgensztern D, Subramanian J, Viswanathan A, Govindan R. Third-line chemotherapy with gemcitabine or docetaxel in patients with advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts Jun 1 2005: 7298.

Subramanian J, Gao F, Sainani N, Viswanathan A, Pillot G, Baggstrom MQ, Sorscher S, Govindan R. Lung cancer in never-smokers: A single institutional experience. ASCO Meeting Abstracts Jun 20 2006: 17044. Subramanian J, Morgensztern D, Govindan R. Pulmonary neuroendocrine carcinomas: A population-based survey. ASCO Meeting Abstracts May 20 2008: 17522.

Subramanian J, Goodgame B, Waqar S, Brantley-Seiders D, Luo J, Young D, Haley J, Chen J, Govindan R. Expression of metastasis related genes in lung cancer in never-smokers; Poster presentation at 12th World Conference on Lung Cancer presentation, 2009

Morgensztern D, Subramanian J, Gao F, Govindan R. Increasing role of tumor histology as a prognostic factor in patients with stage IV; Poster presentation at 12th World Conference on Lung Cancer presentation, 2009

Subramanian J, Morgensztern D, Waqar S, Trinkaus K, Govindan R. Prognostic role of tumor extent (T) and lymph node (N) involvement in stage IV non small cell lung cancer (NSCLC): a surveillance epidemiology end results (SEER) study; Poster presentation at 12th World Conference on Lung Cancer presentation, 2009

Morgensztern D, Goodgame B, Subramanian J, Trinkaus K, Govindan R. Prevalence of early brain metastasis and associated risk factors in patients with non-small cell lung cancer (NSCLC): a SEER Registry study; Poster presentation at 12th World Conference on Lung Cancer presentation, 2009

Subramanian J, Devarakonda S, Gilstrap E, Boehmer L, De Shields T, Williams K, Baggstrom M, Govindan R. A survey of insomnia in patients with non small cell lung cancer (NSCLC); ASCO Meeting Abstracts May 20 2010: e19553

Subramanian J, Vlahiotis A, Frazee S et al. Real world utilization of targeted therapy in cancer treatment. ASCO Meeting Abstracts May 2011: e16618

Khuri F.R., Owonikoko K, Subramanian J et al. Everolimus, an mTOR inhibitor, in combination with docetaxel for second or third line therapy of advanced stage non-small cell lung cancer: A phase II study. ASCO Meeting Abstracts May 2011: e 13601

Nagaraj G, Subramanian J, Gao F et al. Competing mortality risk in patients with resected stage I and II non small cell lung cancer (NSCLC). A Surveillance, Epidemiology AND End Results (SEER) analysis. J Clin Oncol 31, 2013 (suppl abstr 7563).

On Staff At

  • Saint Luke's East Hospital
  • Saint Luke's Hospital of Kansas City
  • Saint Luke's North Hospital–Barry Road
  • Saint Luke's North Hospital–Smithville
  • Saint Luke's South Hospital